Table 1 Contributions of age, sex, and tumor stage to tumor exonic missense mutational burden (TEMMB). Each model was additionally adjusted by recruitment center (IRR and p-values not shown).

From: Burden of unique and low prevalence somatic mutations correlates with cancer survival

 

Age

Sex

Tumor Stage

Age, yrs (IRRa)

p b

Fem (ref)

Male (IRRa)

p b

I-II (ref)

III + (IRRa)

p b

ACC

1.02 [1.01–1.03]

<0.05/31**

1

0.78 [0.57–1.09]

0.14

1

1.35 [0.99–1.85]

0.06

BLCA

1.00 [0.99–1.02]

0.56

1

1.30 [0.95–1.76]

0.08

1

1.37 [1.03–1.80]

<0.05*

BRCA

1.01 [1.01–1.02]

<0.05/31**

1

0.64 [0.35–1.33]

0.19

1

0.78 [0.67–0.91]

<0.05/24**

CESC

1.02 [1.01–1.03]

<0.05/31**

1

—

—

1

1.09 [0.76–1.61]

0.63

CHOL

1.01 [1.00–1.01]

0.07

1

0.93 [0.80–1.08]

0.32

1

0.81 [0.68–0.97]

<0.05*

COAD

1.00 [0.98–1.01]

0.76

1

0.57 [0.39–0.83]

<0.05*

1

0.50 [0.34–0.74]

<0.05/24**

DLBC

1.00 [0.99–1.02]

0.70

1

1.26 [0.80–1.97]

0.31

1

0.57 [0.33–1.01]

<0.05*

ESCA

1.01 [1.00–1.02]

<0.05*

1

0.89 [0.71–1.11]

0.32

1

0.99 [0.83–1.19]

0.95

GBM

1.01 [1.00–1.01]

<0.05/31**

1

0.87 [0.80–0.94]

<0.05/26**

1

—

—

HNSC

1.01 [1.01–1.02]

<0.05/31**

1

1.04 [0.85–1.27]

0.69

1

1.00 [0.80–1.23]

0.98

KICH

1.00 [1.00–1.01]

0.09

1

0.93 [0.79–1.09]

0.37

1

1.25 [1.06–1.47]

<0.05*

KIRC

1.01 [1.01–1.02]

<0.05/31**

1

1.04 [0.91–1.18]

0.57

1

1.01 [0.89–1.16]

0.87

KIRP

1.01 [1.01–1.02]

<0.05/31**

1

1.20 [1.07–1.34]

<0.05/26**

1

1.11 [1.00–1.25]

0.06

LAML

1.01 [1.00–1.02]

<0.05/31**

1

1.11 [0.91–1.36]

0.30

1

—

—

LGG

1.02 [1.02–1.03]

<0.05/31**

1

0.94 [0.85–1.04]

0.21

1

—

—

LIHC

1.00 [1.00–1.01]

0.24

1

1.06 [0.86–1.29]

0.58

1

0.94 [0.76–1.17]

0.59

LUAD

1.00 [0.99–1.01]

0.99

1

1.18 [0.92–1.50]

0.19

1

0.81 [0.62–1.07]

0.13

LUSC

0.99 [0.98–1.01]

0.35

1

1.04 [0.83–1.28]

0.75

1

1.01 [0.80–1.29]

0.91

OV

1.01 [1.00–1.01]

<0.05/31**

1

—

—

1

0.67 [0.50–0.89]

<0.05*

PAAD

1.00 [0.99–1.01]

0.92

1

1.11 [0.97–1.27]

0.14

1

1.11 [0.82–1.53]

0.51

PCPG

1.01 [1.01–1.02]

<0.05/31**

1

1.06 [0.93–1.22]

0.38

1

—

—

PRAD

1.00 [0.99–1.01]

0.84

1

—

—

1

—

—

READ

0.98 [0.96–1.00]

0.05

1

0.92 [0.61–1.38]

0.68

1

0.56 [0.37–0.85]

<0.05*

SARC

1.02 [1.01–1.03]

<0.05/31**

1

1.43 [1.17–1.75]

<0.05/26**

1

—

—

SKCM

1.01 [1.00–1.02]

<0.05*

1

1.39 [1.11–1.72]

<0.05*

1

0.93 [0.74–1.17]

0.51

STAD

1.02 [1.00–1.03]

<0.05*

1

0.95 [0.68–1.32]

0.72

1

0.95 [0.69–1.30]

0.72

THCA

1.01 [1.01–1.02]

<0.05/31**

1

0.96 [0.85–1.08]

0.49

1

1.14 [1.00–1.30]

<0.05*

THYM

1.03 [1.02–1.05]

<0.05/31**

1

1.19 [0.85–1.66]

0.31

1

—

—

UCEC

0.98 [0.96–0.99]

0.14

1

—

—

1

0.79 [0.47–1.37]

0.31

UCS

1.00 [0.98–1.02]

0.89

1

—

—

1

1.20 [0.88–1.63]

0.21

UVM

1.00 [1.00–1.01]

0.43

1

1.13 [0.96–1.34]

0.14

1

0.81 [0.67–0.98]

<0.05**

  1. Older age correlated with high TEMMB in 17 of 31 cancers studied. Effects of male sex and high tumor stage (defined as Stage III or greater) were variable.
  2. aIRR: Incidence rate ratio calculated with multivariate binomial regression, reported with 95% confidence intervals.
  3. bp-values displayed with conventional 0.05 significance cutoff and with cutoff using Bonferroni correction for multiple comparisons (n = 31, 26, 24 for age, sex, stage respectively).
Back to article page